{"id":34503,"date":"2025-07-14T08:01:00","date_gmt":"2025-07-14T06:01:00","guid":{"rendered":"https:\/\/ggba.swiss\/addex-therapeutics-leads-chf-2-million-investment-in-stalicla\/"},"modified":"2025-07-14T12:05:35","modified_gmt":"2025-07-14T10:05:35","slug":"addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/","title":{"rendered":"Addex Therapeutics m\u00e8ne un investissement de CHF 2 millions dans Stalicla"},"content":{"rendered":"\n<p>L\u2019\u00e9cosyst\u00e8me des sciences de la vie \u00e0 Gen\u00e8ve continue de gagner en dynamisme. La soci\u00e9t\u00e9 <a href=\"https:\/\/stalicla.com\/\">Stalicla SA<\/a>, une entreprise biopharmaceutique en phase clinique sp\u00e9cialis\u00e9e dans les traitements de m\u00e9decine de pr\u00e9cision pour les troubles du neurod\u00e9veloppement et les troubles neuropsychiatriques, a obtenu un financement de CHF 2 millions lors d\u2019un tour de table men\u00e9 par l\u2019entreprise genevoise <a href=\"https:\/\/www.addextherapeutics.com\/en\/\">Addex Therapeutics<\/a>. Cet investissement permettra \u00e0 Stalicla de poursuivre ses op\u00e9rations et de faire avancer ses programmes cliniques, alors qu\u2019elle se pr\u00e9pare \u00e0 une lev\u00e9e de fonds de s\u00e9rie C.<\/p>\n\n\n\n<p>Fond\u00e9e avec l\u2019ambition d\u2019appliquer la m\u00e9decine de pr\u00e9cision aux troubles complexes du cerveau, Stalicla a d\u00e9velopp\u00e9 une plateforme propri\u00e9taire, DEPI (Databased Endophenotyping Precision Identification), destin\u00e9e \u00e0 identifier des sous-groupes biologiquement d\u00e9finis au sein de pathologies h\u00e9t\u00e9rog\u00e8nes telles que le trouble du spectre de l\u2019autisme (TSA). L\u2019entreprise s\u2019appr\u00eate \u00e0 lancer des essais de phase 2 pour ses deux principaux candidats, STP1 et STP2, ciblant chacun des sous-populations sp\u00e9cifiques de patients atteints de TSA. En parall\u00e8le, STP7 (Mavoglurant) progresse vers une phase 3, apr\u00e8s la finalisation d\u2019une \u00e9tude d\u2019interaction m\u00e9dicamenteuse men\u00e9e en octobre 2024 et financ\u00e9e par le NIH\u2013National Institute on Drug Abuse (\u00c9tats-Unis).<\/p>\n\n\n\n<p>Dans le cadre de cet accord d\u2019investissement, Tim Dyer, CEO d\u2019Addex Therapeutics, a rejoint le conseil d\u2019administration de Stalicla en tant que pr\u00e9sident. \u00ab Stalicla a construit une plateforme de m\u00e9decine de pr\u00e9cision de r\u00e9f\u00e9rence mondiale pour les troubles du neurod\u00e9veloppement \u00bb, a d\u00e9clar\u00e9 Tim Dyer, mettant en avant le portefeuille clinique de l\u2019entreprise ainsi que le programme STP7 destin\u00e9 aux troubles li\u00e9s \u00e0 l\u2019usage de substances.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un p\u00f4le d\u2019innovation neuroth\u00e9rapeutique<\/h4>\n\n\n\n<p>Cette collaboration refl\u00e8te les synergies croissantes au sein du paysage genevois de l\u2019innovation en neurosciences. En avril 2024, <a href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\">Addex a lanc\u00e9 la spin-off Neurosterix<\/a>, en partenariat avec le fonds am\u00e9ricain Perceptive Advisors, pour acc\u00e9l\u00e9rer le d\u00e9veloppement de modulateurs allost\u00e9riques pour les maladies neurologiques. L\u2019investissement dans Stalicla s\u2019inscrit dans une strat\u00e9gie plus large d\u2019Addex visant \u00e0 soutenir des plateformes neuroth\u00e9rapeutiques prometteuses.<\/p>\n\n\n\n<p>\u00ab Ce financement est une \u00e9tape cl\u00e9 pour s\u00e9curiser notre trajectoire vers plusieurs jalons importants \u00bb, a d\u00e9clar\u00e9 Lynn Durham, CEO de Stalicla. \u00ab Nous sommes reconnaissants du soutien du consortium men\u00e9 par Addex, qui nous permet de continuer \u00e0 faire progresser nos programmes de m\u00e9decine de pr\u00e9cision. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotech genevoise Stalicla obtient un financement pour faire progresser ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.<\/p>\n","protected":false},"author":6,"featured_media":34500,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1180,1188,1154,1239,1141],"class_list":["post-34503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-digital-health-fr-2","tag-healthcare-fr-2","tag-investment-fr-2","tag-neuroscience-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa<\/title>\n<meta name=\"description\" content=\"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa\" \/>\n<meta property=\"og:description\" content=\"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T06:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T10:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Addex Therapeutics m\u00e8ne un investissement de CHF 2 millions dans Stalicla\",\"datePublished\":\"2025-07-14T06:01:00+00:00\",\"dateModified\":\"2025-07-14T10:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\"},\"wordCount\":434,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Digital Health\",\"Healthcare\",\"Investment\",\"Neuroscience\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\",\"name\":\"Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"datePublished\":\"2025-07-14T06:01:00+00:00\",\"dateModified\":\"2025-07-14T10:05:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Stalicla applique la m\u00e9decine de pr\u00e9cision aux troubles du neurod\u00e9veloppement en ciblant des sous-groupes sp\u00e9cifiques via sa plateforme propri\u00e9taire. | \u00a9 Stalicla\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex Therapeutics m\u00e8ne un investissement de CHF 2 millions dans Stalicla\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa","description":"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/","og_locale":"fr_FR","og_type":"article","og_title":"Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa","og_description":"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.","og_url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-07-14T06:01:00+00:00","article_modified_time":"2025-07-14T10:05:35+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Addex Therapeutics m\u00e8ne un investissement de CHF 2 millions dans Stalicla","datePublished":"2025-07-14T06:01:00+00:00","dateModified":"2025-07-14T10:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/"},"wordCount":434,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","keywords":["Biotech","Digital Health","Healthcare","Investment","Neuroscience","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/","url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/","name":"Addex Therapeutics investit CHF 2 millions dans Stalicla | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","datePublished":"2025-07-14T06:01:00+00:00","dateModified":"2025-07-14T10:05:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Stalicla obtient un financement pour ses programmes de m\u00e9decine de pr\u00e9cision dans l\u2019autisme et les troubles li\u00e9s \u00e0 l\u2019usage de substances.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Stalicla-1180x811-1.jpeg","width":1180,"height":811,"caption":"Stalicla applique la m\u00e9decine de pr\u00e9cision aux troubles du neurod\u00e9veloppement en ciblant des sous-groupes sp\u00e9cifiques via sa plateforme propri\u00e9taire. | \u00a9 Stalicla"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Addex Therapeutics m\u00e8ne un investissement de CHF 2 millions dans Stalicla"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=34503"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34503\/revisions"}],"predecessor-version":[{"id":34505,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34503\/revisions\/34505"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/34500"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=34503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=34503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=34503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}